Active Substance: Lisinopril (as dihydrate).
Overview
Welcome to Dwaey, specifically on LISINO 10mg page.
This medicine contains an important and useful components, as it consists of
Lisinopril (as dihydrate)is available in the market in concentration
Lisinopril
Hypovolaemia, hyperkalaemia, collagen vascular disease, valvular stenosis; before, during or immediately after anaesthesia, preexisting renal insufficiency, unilateral renal artery stenosis. Children <6 yr. Assess renal function. May impair ability to drive or operate machinery. Lactation: Not known if excreted into breast milk; not recommended
Heart failure, Myocardial infarction, Diabetic nephropathy, Hypertension
History of angioedema related to previous treatment with ACE inhibitors, hereditary or idiopathic angioedema. Bilateral renal artery stenosis. Pregnancy (2nd or 3rd trimester), lactation.
>10% Dizziness (5-12%) 1-10% Cough (4-9%),Headache (4-6%),Hyperkalemia (2-5%),Diarrhea (3-4%),Hypotension (1-4%),Chest pain (3%),Fatigue (3%),Nausea/vomiting (2%),Kidney disease, of AMI patients (2%),Rash (1-2%) <1% Immune hypersensitivity reaction,Psoriasis,Angioedema of the face, lips, throat; intestinal angioedema,Anuria,Atrial tachycardia,Acute renal failure,Arthralgia,Alopecia,Atrial fibrillation,Bone marrow suppression,Cutaneous pseudolymphoma,Hypersomnia,Leukopenia,Mood changes,Pancreatitis,Skin infections Potentially Fatal: Severe hypotension, angioedema.
4
Lisinopril competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.
May enhance hypotensive effect w/ diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect w/ NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia w/ K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate. Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function w/ aliskiren in patients w/ diabetes or renal impairment.
Information not available